TLX Telix Pharmaceuticals Limited
Company Analysis
Latest News
Telix Pharmaceuticals Limited Q1 2026 Earnings Preview: What Analysts Expect on July 02, 2026
Analysts expect Telix Pharmaceuticals to report first-quarter revenue of approximately $230 million and a consensus EPS of -$0.01, while the current stock...
🟢 TLX extends move to 5.1% up
TLX is trading at $11.20, up 5.1% versus the comparison close of $10.66 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 TLX is trading 4.7% up today as pipeline updates and ASCO visibility boost sentiment
TLX is trading 4.7% up today at $11.16 as buyers step in following recent weakness and positive clinical developments. • Telix is highlighting its...
🟢 Telix Pharmaceuticals Limited is trading 4.50% up in pre-market
TLX is trading at $11.14, up 4.50% in pre-market.
Telix Pharmaceuticals Secures Vanguard Backing with New 5% Stake
Telix Pharmaceuticals disclosed in an ASX filing that The Vanguard Group has become a substantial shareholder. The investment firm now holds a 5.217% voting...
Telix Pharmaceuticals Limited Q1 2026 Earnings Preview: What Analysts Expect on June 25, 2026
Analysts expect Telix Pharmaceuticals to report Q1 2026 revenue of US$230 million and an EPS of -US$0.01, while the current share price of A$14.21 remains well...
🟢 Telix Pharmaceuticals Limited extends move to 5.0% up
TLX is trading at $10.06, up 5.0% versus the comparison close of $9.58 during regular trading. This is a price-movement alert; no separate company-specific...
Telix Pharmaceuticals Limited Q1 2026 Earnings Preview: What Analysts Expect on June 18, 2026
Consensus estimates for Q1 2026 anticipate Telix will report revenue of $230 million and an EPS of -$0.01, while the current stock price of $13.60 trades...